Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment By Investing.com
Update: 2025-11-03
Description
Tscan Therapeutics, a clinical-stage biotech, has announced a significant shift in focus, pausing its solid tumor trial and refocusing on blood cancer research, particularly its TSC-one-oh-one program targeting acute myeloid leukemia and myelodysplastic syndromes. This strategic move follows a positive FDA meeting and aims to save up to $45 million annually, securing funds until mid-2027. The company will reduce its workforce by 30%, impacting 66 employees, and plans to share early solid tumor trial results and start its pivotal TSC-one-oh-one trial in 2026.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
